Caricamento...
A PHASE II TRIAL OF ERLOTINIB IN RECURRENT SQUAMOUS CELL CARCINOMA OF THE CERVIX: A GYNECOLOGIC ONCOLOGY GROUP STUDY
OBJECTIVES: To determine the proportion of patients with tumor response, the proportion who survived progression-free for at least six months (PFS ≥ 6 months) and the frequency and severity of toxicities of patients with recurrent squamous cell carcinoma of the uterine cervix treated with erlotinib....
Salvato in:
| Autori principali: | , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2009
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2722934/ https://ncbi.nlm.nih.gov/pubmed/19574787 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/IGC.0b013e3181a83467 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|